Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis

Inclusion Criteria: * Patients with a diagnosis of endogenous anterior uveitis or panuveitis * Patients with ≥ 50 anterior chamber cells as observed by slit lamp microscopy (criterion for evaluation of signs 4) * Patients requiring more frequent instillation of 0.1% betamethasone sodium phosphate ophthalmic solution than the regular frequency specified in its dosage and administration (3 - 4 times/day) * Patients aged ≥ 12 years (on the day of obtaining informed consent) who were able to actuate symptoms * Patients giving written informed consent prior to initiation of the study Exclusion Criteria: * Patients who did not meet all of the above inclusion criteria * Patients initiating treatment with systemic administration of any corticosteroid, non-steroidal anti-inflammatory drug, antiphlogistic enzyme or immunosuppressive drug within 2 weeks before instillation of the investigational drug * Patients receiving topical injection of any corticosteroid in eyes before instillation of the investigational product(solution formulation: within 1 week before instillation of the investigational product, depot formulation: within 2 weeks before instillation of the investigational product) * Patients receiving instillation of any corticosteroid, non-steroidal anti-inflammatory ophthalmic solution or antiphologistic enzyme within 12 hours before instillation of the investigational drug * Patients with glaucoma or ocular hypertension * Patients with corneal erosion or corneal ulcer * Patients with any viral, bacterial or fungal keratoconjunctival disease or suspected with eye infection * Patients with allergy to similar drugs of difluprednate * Patients requiring use of contact lens during the study period * Women who were or might be pregnant, or lactating women * Patients participating in another clinical study within 3 months before initiation of the present study